

CONTENTS

LIST OF TABLES	i - viii
LIST OF FIGURES	ix - xv
CHAPTER 1 INTRODUCTION	1-9
1.1 Introduction	2
1.2 Proposed plan of work	7
CHAPTER 2 LITERATURE REVIEW	10-118
2.1 Peptide and DNA delivery	11
2.1.1 Introduction	11
2.1.2 Future research in drug delivery	12
2.2 Liposomes as delivery systems for peptides and DNA	13
2.2.1 Introduction	13
2.2.2 Structure and classification of liposomes	14
2.2.3 Materials used in the preparation of liposomes	14
2.2.3.1 Phospholipids	14
2.2.3.2 Sphingolipids	15
2.2.3.3 Cholesterol	15
2.2.3.4 Charged phospholipids	16
2.2.3.5 Other substances	16
2.2.4 Mechanism of liposome formulation	17
2.2.5 Preparation of liposomes	19
2.2.5.1 Mechanical dispersion methods	19
2.2.5.2 Solvent dispersion methods	21
2.2.5.3 Methods based on detergent removal by	23
2.2.5.4 Methods based on size transformation and fusion	23
2.2.6 Procedures for the removal of unencapsulated drug from the liposomal suspension	23
2.2.7 Characterization of liposomes	25
2.2.7.1 Physical characterization	25
2.2.7.2 Chemical characterization	28
2.2.8 Stability of liposomes	28
2.2.8.1 Physical stability	29
2.2.8.2 Chemical stability	29
2.2.8.3 Approaches to improve liposomal stability	30
2.2.9 Pharmacokinetics and fate of liposomes	31
2.2.10 Applications of liposomes	33
2.3 Sterically stabilized liposomes	36
2.3.1 Introduction	36
2.3.2 Agents used for steric stabilization	37
2.3.3 Properties of PEG-grafted liposomes	41
2.3.3.1 Physiochemical properties	41
2.3.4 The Immune system	47
2.3.4.1 Innate immunity	47
2.3.4.2 Acquired immunity	48

2.3.5	Opsonization and Phagocytosis	51
2.3.5.1	Major specialized opsonins of normal blood include	52
2.3.5.2	Minor opsonins	53
2.3.6	Avoidance of MPS uptake and its consequences	54
2.3.7	The surface of long circulating liposomes	55
2.3.7.1	Molecular brush: structure and protective properties	57
2.3.7.2	Interactions of protective polymers with components of biological systems	58
2.3.7.3	Approaches to the development of better liposome surface modifiers	60
References		62
2.4	Profile of cyclosporine (CsA)	74
2.4.1	Introduction	74
2.4.2	Chemistry	74
2.4.2.1	Structural formula	74
2.4.2.2	Structure	74
2.4.3	Pharmacology	74
2.4.3.1	Mechanism of action	74
2.4.3.2	Drug disposition and pharmacokinetics	75
2.4.3.3	Cellular mechanism of action of cyclosporine	76
2.4.3.4	Therapeutic uses	77
2.4.3.5	Dosage and administration	78
2.4.3.6	Toxicity	78
2.4.3.7	Drug interactions	79
2.4.3.8	Precautions	79
2.4.3.9	Laboratory tests	79
2.4.3.10	Adverse reactions	80
2.4.4	Quantitative analytical profile of cyclosporine	80
2.4.4.1	Chromatographic techniques	80
2.4.4.2	Other methods	82
References		85
2.5	Profile of Leuprolide acetate	89
2.5.1	Introduction	89
2.5.2	Description	89
2.5.2.1	Molecular formula	89
2.5.2.2	Molecular weight	89
2.5.3	Physiochemical properties	90
2.5.3.1	Solubility	90
2.5.3.2	Ionisation constant	90
2.5.4	Clinical pharmacology	90
2.5.4.1	LHRH in prostate cancer	91
2.5.4.2	LHRH in melanoma	93

	2.5.4.3	Expression of LHRH and LHRH receptors	94
	2.5.4.4	Antiproliferative activity of LHRH	95
	2.5.4.5	Uses	95
	2.5.4.6	Pharmacokinetics	96
	2.5.4.7	Distribution	96
	2.5.4.8	Metabolism	96
	2.5.4.9	Excretion	96
	2.5.4.10	Indications	96
	2.5.4.11	Dosage and administration	97
	2.5.4.12	Contraindications	98
	2.5.4.13	Adverse effects	98
	2.5.4.14	Overdosage	99
	2.5.4.15	Pharmaceutical precautions	99
	2.5.5	Quantitative methods	99
	2.5.5.1	HPLC	99
References			101
2.6	DNA		107
	2.6.1	Introduction	107
	2.6.2	Calf thymus DNA	107
	2.6.3	Gene delivery	107
	2.6.4	Production of liposomes for gene delivery	109
	2.6.5	Liposomes for prolonged circulation	111
	2.6.6	Quantitative methods	114
	2.6.6.1	Ultraviolet (uv) spectrophotometry	114
	2.6.6.2	Chemiluminescence method	114
	2.6.6.3	Fluorescence method	115
References			116
	CHAPTER 3 ANALYTICAL METHODS		119-161
3.1	Introduction		120
3.2	Experimental		120
	3.2.1	Drugs	120
	3.2.2	Reagents	120
	3.2.3	Apparatus	120
	3.2.4	Estimation of phosphatidyl choline in liposomes	120
	3.2.4.1	Solutions	121
	3.2.4.2	Principle	121
	3.2.4.3	Procedure for calibration curve	121
	3.2.4.4	Stability and selectivity	123
	3.2.4.5	Estimation of phosphatidyl choline from liposomes/ supernatant	124
	3.2.5	Estimation of cholesterol in liposomes	124
	3.2.5.1	Solutions	124
	3.2.5.2	Principle	125
	3.2.5.3	Procedure for calibration curve	125
	3.2.5.4	Stability and selectivity	125

	3.2.5.5	Estimation of cholesterol from liposomes/ supernatant	126
3.2.6		Estimation of Cyclosporine in liposomes	127
	3.2.6.1	Solutions	127
	3.2.6.2	Procedure for calibration curve	128
	3.2.6.3	Stability and selectivity	128
	3.2.6.4	Estimation of cyclosporine from liposomes/ supernatant	128
3.2.7		Estimation of Leuprolide acetate in 0.1n sodium hydroxide	131
	3.2.7.1	Solutions	131
	3.2.7.2	Procedure for calibration curve	131
	3.2.7.3	Stability and selectivity	131
	3.2.7.4	Estimation of Leuprolide acetate from liposomes/ supernatant	131
3.2.8		Estimation of DNA in Tris buffer pH 8.0	134
	3.2.8.1	Solutions	134
	3.2.8.2	Procedure for calibration curve	134
	3.2.8.3	Stability and selectivity	135
	3.2.8.4	Estimation of DNA from liposomes/ supernatant	135
3.2.9		Estimation of Leuprolide acetate in phosphate buffer saline (PBS)	138
	3.2.9.1	Solutions	138
	3.2.9.2	Procedure for calibration curve	138
	3.2.9.3	Stability and selectivity	138
3.2.10		Estimation of DNA in PBS	141
	3.2.10.1	Solutions	141
	3.2.10.2	Procedure for calibration curve	141
	3.2.10.3	Stability and selectivity	141
3.2.11		Estimation of Polyethylene glycol derivatives in liposomes	143
	3.2.11.1	Solutions	143
	3.2.11.2	Procedure for calibration curve	144
	3.2.11.3	Stability and selectivity	144
	3.2.11.4	Estimation of polyethylene glycol derivatives from liposomes/ supernatant	145
3.3		Results and discussion	148
	3.3.1	Estimation of phosphatidyl choline in liposomes	148
	3.3.2	Estimation of cholesterol in liposomes	149
	3.3.3	Estimation of cyclosporine in liposomes	151
	3.3.4	Estimation of leuprolide acetate in liposomes	152
	3.3.5	Estimation of DNA in liposomes	154
	3.3.6	Estimation of leuprolide acetate in phosphate buffer saline, pH 7.4 (PBS)	155

3.3.7	Estimation of DNA in phosphate buffer saline, pH 7.4 (PBS)	156
3.3.8	Estimation of polyethylene glycol derivatives in liposomes	157
3.3.8.1	Estimation of methoxy polyethylene glycol 5000 activated with cyanuric chloride- phosphatidyl ethanolamine conjugate (MPEG5000-CC-PE)	157
3.3.8.2	Estimation of methoxy polyethylene glycol 2000 activated with cyanuric chloride- phosphatidyl ethanolamine conjugate (MPEG2000-CC-PE)	159
References		161
CHAPTER 4 PREPARATION OF LIPOSOMES		162-237
4.1	Introduction	163
4.2	Experimental	164
4.2.1	Drugs	164
4.2.2	Reagents	165
4.2.3	Equipment	165
4.2.4	Solutions	165
4.2.5	Preparation of neutral and charged liposomes containing cyclosporine	166
4.2.6	Leuprolide acetate and DNA liposomes	177
4.2.6.1	Preparation of conventional liposomes containing leuprolide acetate	177
4.2.6.2	Preparation of conventional liposomes containing DNA	187
4.2.7	Electrolyte induced flocculation test	190
4.2.8	Preparation of sterically stabilized liposomes containing leuprolide acetate and DNA	193
4.2.8.1	Introduction	193
4.2.8.2	Synthesis of methoxy polyethylene glycol 5000 activated with cyanuric chloride (MPEG5000-CC)	194
4.2.8.3	Synthesis of methoxy polyethylene glycol 5000 activated with cyanuric chloride-phosphatidyl ethanolamine conjugate (MPEG5000-CC-PE)	195
4.2.8.4	Synthesis of methoxy polyethylene glycol 2000 activated with cyanuric chloride (MPEG2000-CC)	204
4.2.8.5	Synthesis of methoxy polyethylene glycol 2000 activated with cyanuric chloride-phosphatidyl ethanolamine conjugate (MPEG2000-CC-PE)	204

	4.2.8.6	Preparation of liposomes using MPEG5000-CC-PE and MPEG2000- CC-PE	205
4.3		Results and discussion	220
	4.3.1	Optimisation of the preparation of charged liposomes of cyclosporine	220
		4.3.1.1 Influence of formulation process parameters	220
		4.3.1.2 Conditions for preparation of cyclosporine containing liposomes. Influence of formulation component variables	222
	4.3.2	Optimization of the preparation of leuprolide acetate liposomes	225
		4.3.2.1 Multiple linear regression	225
		4.3.2.2 Contour plots	227
		4.3.2.3 ANN structure	227
		4.3.2.4 Comparison of ANN and MLR	228
	4.3.3	Optimization of the preparation of conventional liposomes of DNA	229
		4.3.3.1 Conditions for preparation of DNA containing liposomes	231
	4.3.4	Sterically stabilized liposomes of leuprolide acetate and DNA using PEG derivatives	232
		References	235
		CHAPTER 5 CHARACTERIZATION OF LIPOSOMES	238-262
5.1		Introduction	239
5.2		Experimental	239
	5.2.1	Reagents	239
	5.2.2	Apparatus	239
	5.2.3	Solutions	240
	5.2.4	Characterization	240
		5.2.4.1 Morphology and lamellarity	240
		5.2.4.2 Size	240
		5.2.4.3 Scanning electron microscopy (SEM)	240
		5.2.4.4 Differential scanning calorimetry (DSC)	241
		5.2.4.5 Entrapped volume	241
		5.2.4.6 Zeta potential	241
		5.2.4.7 Electrolyte induced flocculation test	241
		5.2.4.8 Drug entrapment	241
5.3		Results and discussion	257
	5.3.1	Morphology and lamellarity	257
	5.3.2	Particle size	257
	5.3.3	Differential scanning calorimetry (DSC)	258
	5.3.4	Zeta potential	259

5.3.5	Entrapped volume	259
5.3.6	Electrolyte induced flocculation	260
5.3.7	Drug entrapment	260
References		262
CHAPTER 6 IN VITRO DRUG RELEASE KINETICS FROM LIPOSOMES		263-285
6.1	Introduction	264
6.2	Experimental	265
6.2.1	Reagents	265
6.2.2	Solutions	265
6.2.3	Studies of kinetics of drug release from liposomes	266
6.2.4	Data analysis	266
6.3	Results and discussion	279
6.3.1	Release studies of charged liposomes containing cyclosporine	279
6.3.2	Release studies of conventional liposomes containing leuprolide acetate and DNA	281
6.3.3	Release studies of sterically stabilized liposomes containing leuprolide acetate and DNA	282
6.3.4	Conclusions	284
References		285
CHAPTER 7 STABILITY TESTING OF LIPOSOMES		286-308
7.1	Introduction	287
7.2	Experimental	289
7.2.1	Reagents	289
7.2.2	Apparatus	289
7.2.3	Solutions	289
7.2.4	Stability studies of Cyclosporine (CsA) loaded liposomal formulations	289
7.2.5	Stability studies of conventional and sterically stabilized liposomes containing leuprolide acetate	291
7.2.6	Stability studies of conventional and sterically stabilized liposomes containing DNA	292
7.3	Results and discussion	303
7.3.1	Cyclosporine loaded liposomes	303
7.3.2	Leuprolide acetate loaded liposomes	305
7.3.3	DNA loaded liposomes	306
7.4	Conclusions	307
References		308
CHAPTER 8 IN VITRO IMMUNOSUPPRESSIVE STUDY OF CYCLOSPORINE LIPOSOMES		309-320
8.1	Introduction	310
8.2	Experimental	312
8.2.1	Chemicals	312

8.2.2	Preparation of splenic lymphocytes (splenocyte) suspension	312
8.2.3	Treatment of splenocytes with CsA and liposomal CsA	312
8.2.4	DNA analysis by flow cytometry	313
8.2.5	Analysis of CD4 and CD8 cells	313
8.2.6	Statistical analysis	314
8.3	Results and discussion	318
8.3.1	Studies on apoptosis by flow cytometry	318
8.3.2	Effects on CD4 and CD8 cells	319
8.3.3	Conclusion	319
	References	320
	CHAPTER 9 IN VITRO CYTOTOXICITY STUDY OF LEUPROLIDE ACETATE LIPOSOMES	321-331
9.1	Introduction	322
9.2	Measurement endpoints for cytotoxicity	322
9.3	Cytotoxicity protocols	323
9.4	Principle of the MTT assay	324
9.4.1	Advantages of MTT method	325
9.5	Experimental	326
9.5.1	Cell lines	326
9.5.2	Solutions	326
9.5.2.1	MTT solution	326
9.5.2.2	Solution of leuprolide acetate and its liposomal formulations	326
9.6	Results and discussion	328
9.6.1	Leuprolide acetate and its liposomes	328
	References	329
	CHAPTER 10 RADIOLABELING OF LIPOSOMES	332-361
10.1	Introduction	333
10.2	Chemistry of technetium	334
10.3	Reduction of $^{99m}\text{TcO}_4^-$	334
10.4	Labeling with reduced technetium	334
10.5	Hydrolysis of reduced technetium and tin	335
10.6	Materials	335
10.7	Radiolabeling of Cyclosporine, leuprolide acetate, DNA and their liposomal formulations	335
10.7.1	Labeling efficiency	335
10.7.2	Stability study of ^{99m}Tc -labeled complex	336
10.7.3	DTPA challenging test	336
10.7.4	Optimization of radiolabeling of Cyclosporine and its liposomal formulations	337
10.7.5	Optimization of radiolabeling of Leuprolide and its liposomal formulations	344

10.7.6	Optimization of radiolabeling of DNA and its liposomal formulations	350
10.8	Results and discussion	356
10.8.1	Radiolabeling of Cyclosporine and its liposomes	356
10.8.1.1	pH of the complex	356
10.8.1.2	Incubation time	356
10.8.1.3	SnCl ₂ .2H ₂ O concentration	356
10.8.1.4	Stability of the labeled complex	357
10.8.2	Radiolabeling of Leuprolide and its liposomes	357
10.8.2.1	pH of the complex	358
10.8.2.2	Incubation time	358
10.8.2.3	SnCl ₂ .2H ₂ O concentration	358
10.8.2.4	Stability of the labeled complex	358
10.8.3	Radiolabeling of DNA and its liposomes	359
10.8.3.1	pH of the complex	359
10.8.3.2	Incubation time	359
10.8.3.3	SnCl ₂ .2H ₂ O concentration	360
10.8.3.4	Stability of the labeled complex	360
References		361

CHAPTER 11 IN VIVO STUDIES 362-413

11.1	Introduction	363
11.2	Experimental	363
11.2.1	Selection of animals	363
11.2.2	Tumor implantation	363
11.2.3	Blood kinetic studies	364
11.2.4	Biodistribution studies	364
11.2.5	Gamma scintigraphic imaging	364
11.2.6	Data Analysis	365
11.2.7	<i>In vitro</i> testing for drug retention in liposomes	365
11.3	Results and discussion	402
11.3.1	General methodology	402
11.3.2	Cyclosporine and its liposomes	403
11.3.3	Leuprolide acetate and its liposomes	406
11.3.4	DNA and its liposomes	408

References		412
------------	--	-----

CHAPTER 12 NEPHROTOXICITY STUDY OF CYCLOSPORINE LIPOSOMES 414-423

12.1	Introduction	415
12.2	Four drug-related renal syndromes	415
12.2.1	Acute renal failure	415
12.2.1.1	Prerenal acute renal failure	416
12.2.1.2	Three types of intrinsic acute renal failure	416
12.2.2	Nephrotic syndrome	418
12.2.3	Chronic renal insufficiency	418

12.3	Experimental procedure	418
12.3.1	Nephrotoxicity study of cyclosporine and its liposomal formulations	418
12.4	Results and discussion	419
12.4.1	Nephrotoxicity studies	419
	References	423
	CHAPTER 13 SUMMARY AND CONCLUSION	424-447
13.1	Introduction	425
13.2	Cyclosporine	426
13.3	Leuprolide acetate	426
13.4	DNA	426
13.5	Preparation of liposomes containing Cyclosporine A, Leuprolide acetate and DNA	427
13.5.1	Cyclosporine	427
13.5.2	Leuprolide acetate	428
13.5.3	DNA	430
13.6	Characterization of the liposomal formulations	431
13.7	Drug release kinetic study	432
13.8	Stability study of the prepared liposomes	433
13.8.1	Cyclosporine a liposomes	434
13.8.2	Leuprolide acetate liposomes	434
13.8.3	DNA liposomes	435
13.9	<i>In vitro</i> evaluation of CsA liposomal suspensions on mouse splenocytes	435
13.10	<i>In vitro</i> cytotoxicity studies of leuprolide acetate liposomes	436
13.11	<i>In vivo</i> biodistribution studies by radiolabeling technique	437
13.12	Nephrotoxicity studies of the cyclosporine liposomal suspensions	444
13.13	Conclusions	444
	List of publication	448
	List of papers presented in conferences	449